Q-omics provides the consensus-scored RRS1 profile across patient tissues and cancer cell-line models. RRS1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RRS1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, RRS1 protein abundance shows 21,262 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where RRS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRS1 survival associations across molecular data types. RRS1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRS1 RNA expression–survival associations across cancer types. High RRS1 expression shows unfavorable associations in KIRP, UVM, HNSC, LIHC, LUAD and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RRS1 RNA expression.
This table summarizes RRS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RRS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRS1 shows higher tumor expression in COAD, HNSC, KIRC, STAD, KIRP and LUAD. The COAD box plot shows higher RRS1 RNA expression in tumor versus normal tissue (log2 FC = +2.017, t-test p < 0.001).
This table shows molecular features associated with RRS1 in patient tissues and cancer cell lines. In patient samples, RRS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RRS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
